Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Terbinafine can cause hair loss.

Lipid nanoparticles improve drug delivery through the skin, offering stability, controlled release, and better compatibility with skin.

Minoxidil, when applied to the scalp, can stimulate hair growth but effects vary, stop if treatment ends, and it may cause side effects like fluid retention.

Skin diseases are common and can significantly affect people's lives; better outcome measures and ethical clinical trials are needed to improve dermatology care.

Oral cyclosporin doesn't stop hair loss.

Microneedling is a promising, simple, and cost-effective treatment for hair loss that works well with other therapies.

Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.

Cyclosporin doesn't stop hair loss.

Nanocarrier-based treatments show promise for better hair growth in androgenetic alopecia but need more research.

New treatment using Minoxidil and EGCG with ionic liquids improves hair growth and quality for hair loss.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Taking Dutasteride with Ketoconazole can increase Dutasteride's effects and side effects.

Low vitamin D levels may affect ovulation and progesterone in infertile women.

New treatments like nanotechnology show promise in improving skin cancer therapy.

Leptin, a hormone from fat cells, affects immune responses and can influence skin diseases and hair growth.

Zinc is crucial for skin health and treating various skin disorders.

Finasteride-loaded proniosomes effectively promote hair growth in mice.

Food intake, not genetics, affects how the body processes tadalafil and finasteride.

Supplemented Erzhi Wan may help regrow hair in male pattern baldness by affecting certain cell signaling pathways.

Men and women respond differently to drugs for COVID-19, high cholesterol, and diabetes, which suggests a need for personalized treatments.

Polycystic Ovary Syndrome should be seen mainly as a condition of excess male hormones, with a focus on this in its definition.

The report concludes that PCOS is mainly a condition of excess male hormones and its definition may change as new information is discovered.

Most women with excess male hormones have Polycystic Ovary Syndrome, and hormonal therapy can improve symptoms but may cause side effects.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Experts recommend using evidence-based methods to diagnose and treat hirsutism, focusing on symptoms and underlying causes.

Most women referred for excess male hormone symptoms had polycystic ovary syndrome (PCOS), with other conditions being less common.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.